Camp4 Therapeutics vs NewAmsterdam Pharma
CAMP and NAMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAMP and NAMS compare
Camp4 Therapeutics grew revenue faster over the last twelve months (40.2% versus −88.9% for NewAmsterdam Pharma).
Camp4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2544% compared with −3644% at NewAmsterdam Pharma.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAMP | NAMS |
|---|---|---|
| Size and price | ||
| Market cap | $251M | – |
| Share price | $4.00 | $19.39 |
| Change, 1 year | −2.4% | −49.4% |
| Change, 5 years | −98.2% | 98.1% |
| Beta (5Y) | 1.48 | 1.57 |
| Employees | 48 | 100 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 59.5× | – |
| FCF yield | −11.4% | – |
| Growth | ||
| Revenue growth (TTM) | 40.2% (better) | −88.9% |
| Profitability | ||
| Operating margin | −1254% (better) | −3432% |
| Net margin | −2544% (better) | −3644% |
| FCF margin | −681% (better) | −2018% |
| Return on equity | −546% | −36.8% (better) |
| Return on invested capital | – | −1046% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 4.70 | 9.03 (better) |
| Altman Z-score | −4.47 | – |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 66.5% | – |
| Held by insiders | 21.7% | 22.0% |
| Insider net buying, 12 months | −$2.4M (better) | −$63.0M |
| Short interest, % of float | 6.6% | – |
Go deeper
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.